Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 2-3/2010

01-04-2010

The Premenstrual Syndrome and Fibromyalgia—Similarities and Common Features

Authors: Daniela Amital, Calanit Herskovitz, Leah Fostick, Alysa Silberman, Yariv Doron, Joseph Zohar, Alek Itsekson, Matityahu Zolti, Alan Rubinow, Howard Amital

Published in: Clinical Reviews in Allergy & Immunology | Issue 2-3/2010

Login to get access

Abstract

The aim of the study was to assess the clinical similarities and common features of fibromyalgia syndrome (FM) and premenstrual dysphoric syndrome (PMDD). Thirty young patients who met the diagnostic criteria for PMDD were included in the study and compared to 26 women belonging to the medical staff of a general psychiatry department. All enrollees were interviewed and examined by a skilled physician. They completed the following nine survey items: demographic information, clinical health assessment questionnaire, fibromyalgia impact questionnaire, sleep and fatigue questionnaires, Sheehan disability scales, SF-36 assessment for quality of life, visual analog scale for pain, Mini International Neuropsychiatric Interview (MINI) questionnaire (assessment of coexistent psychiatric conditions), and the premenstrual severity scale. Additionally, each individual underwent a physical examination measuring the classical tender points and was asked to describe the distribution and continuum of her pain or tenderness. The PMDD group scored significantly higher in the measures pain and tenderness as well as in severity of premenstrual symptoms compared to the control group. Five patients in the PMDD group and none in the control group had FM. Quality of life measured by the SF-36 was higher in the control group than in the PMDD group and correlated with the degree of tenderness reported. Psychiatric comorbidity was significantly more common in the PMDD group, affecting 16 of the 30 PMDD patients compared to only three of the 26 control patients. In this study, patients with PMDD were found to have higher levels of tenderness, higher psychiatric comorbidity, greater level of physical disabilities, and a lower quality of life. These parameters were highly correlated with a lower pain threshold.
Literature
1.
go back to reference Campbell EM, Peterkin D, O’Grady K, Sanson-Fisher R (1997) Premenstrual symptoms in general practice patients. Prevalence and treatment. J Reprod Med 42:637–646PubMed Campbell EM, Peterkin D, O’Grady K, Sanson-Fisher R (1997) Premenstrual symptoms in general practice patients. Prevalence and treatment. J Reprod Med 42:637–646PubMed
2.
go back to reference Steiner M, Born L (2000) Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 15(Suppl 3):S5–S17PubMed Steiner M, Born L (2000) Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 15(Suppl 3):S5–S17PubMed
3.
go back to reference Alonso C, Loevinger BL, Muller D, Coe CL (2004) Menstrual cycle influences on pain and emotion in women with fibromyalgia. J Psychosom Res 57:451–458CrossRefPubMed Alonso C, Loevinger BL, Muller D, Coe CL (2004) Menstrual cycle influences on pain and emotion in women with fibromyalgia. J Psychosom Res 57:451–458CrossRefPubMed
4.
go back to reference Straneva PA, Maixner W, Light KC, Pedersen CA, Costello NL, Girdler SS (2002) Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol 21:358–367CrossRefPubMed Straneva PA, Maixner W, Light KC, Pedersen CA, Costello NL, Girdler SS (2002) Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol 21:358–367CrossRefPubMed
5.
go back to reference Facchinetti F, Martignoni E, Petraglia F, Sances MG, Nappi G, Genazzani AR (1987) Premenstrual fall of plasma beta-endorphin in patients with premenstrual syndrome. Fertil Steril 47:570–573PubMed Facchinetti F, Martignoni E, Petraglia F, Sances MG, Nappi G, Genazzani AR (1987) Premenstrual fall of plasma beta-endorphin in patients with premenstrual syndrome. Fertil Steril 47:570–573PubMed
6.
go back to reference Giannini AJ, Martin DM, Turner CE (1990) Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 20:279–284PubMed Giannini AJ, Martin DM, Turner CE (1990) Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 20:279–284PubMed
7.
go back to reference Tulenheimo A, Laatikainen T, Salminen K (1987) Plasma beta-endorphin immunoreactivity in premenstrual tension. Br J Obstet Gynaecol 94:26–29PubMed Tulenheimo A, Laatikainen T, Salminen K (1987) Plasma beta-endorphin immunoreactivity in premenstrual tension. Br J Obstet Gynaecol 94:26–29PubMed
8.
go back to reference Giannini AJ, Melemis SM, Martin DM, Folts DJ (1994) Symptoms of premenstrual syndrome as a function of beta-endorphin: two subtypes. Prog Neuropsychopharmacol Biol Psychiatry 18:321–327CrossRefPubMed Giannini AJ, Melemis SM, Martin DM, Folts DJ (1994) Symptoms of premenstrual syndrome as a function of beta-endorphin: two subtypes. Prog Neuropsychopharmacol Biol Psychiatry 18:321–327CrossRefPubMed
9.
go back to reference Taskin O, Gokdeniz R, Yalcinoglu A, Buhur A, Burak F, Atmaca R et al (1998) Placebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral beta-endorphin concentrations in premenstrual syndrome. Hum Reprod 13:2402–2405CrossRefPubMed Taskin O, Gokdeniz R, Yalcinoglu A, Buhur A, Burak F, Atmaca R et al (1998) Placebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral beta-endorphin concentrations in premenstrual syndrome. Hum Reprod 13:2402–2405CrossRefPubMed
10.
go back to reference Yonkers KA (1997) Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? J Clin Psychiatry 58(Suppl 3):62–67PubMed Yonkers KA (1997) Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? J Clin Psychiatry 58(Suppl 3):62–67PubMed
11.
go back to reference Kim DR, Gyulai L, Freeman EW, Morrison MF, Baldassano C, Dube B (2004) Premenstrual dysphoric disorder and psychiatric co-morbidity. Arch Womens Ment Health 7:37–47CrossRefPubMed Kim DR, Gyulai L, Freeman EW, Morrison MF, Baldassano C, Dube B (2004) Premenstrual dysphoric disorder and psychiatric co-morbidity. Arch Womens Ment Health 7:37–47CrossRefPubMed
12.
go back to reference Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG et al (1997) Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 154:1734–1740PubMed Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG et al (1997) Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 154:1734–1740PubMed
13.
go back to reference Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition (DSM-IV) (1994) American Psychiatric Association, Washington D.C. Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition (DSM-IV) (1994) American Psychiatric Association, Washington D.C.
14.
go back to reference Thys-Jacobs S, Alvir JM, Fratarcangelo P (1995) Comparative analysis of three PMS assessment instruments–the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 31:389–396PubMed Thys-Jacobs S, Alvir JM, Fratarcangelo P (1995) Comparative analysis of three PMS assessment instruments–the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 31:389–396PubMed
15.
go back to reference Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMed Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMed
16.
go back to reference Guy W (1976) Clinical global impressions ECDEU assessment manual for psychopharmacology. ECDEU: National institute of Health pp. 218–22 Guy W (1976) Clinical global impressions ECDEU assessment manual for psychopharmacology. ECDEU: National institute of Health pp. 218–22
17.
go back to reference Sheehan DV (1983) The anxiety disease. Charles and Scribner, New York Sheehan DV (1983) The anxiety disease. Charles and Scribner, New York
18.
19.
go back to reference McHorney CA, Ware JE Jr, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263CrossRefPubMed McHorney CA, Ware JE Jr, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263CrossRefPubMed
20.
go back to reference Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS et al (1995) The development of a Clinician-Administered PTSD Scale. J Trauma Stress 8:75–90CrossRefPubMed Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS et al (1995) The development of a Clinician-Administered PTSD Scale. J Trauma Stress 8:75–90CrossRefPubMed
21.
go back to reference Burckhardt CS, Clark SR, Bennett RM (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733PubMed Burckhardt CS, Clark SR, Bennett RM (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733PubMed
22.
go back to reference Goldenberg DL, Mossey CJ, Schmid CH (1995) A model to assess severity and impact of fibromyalgia. J Rheumatol 22:2313–2318PubMed Goldenberg DL, Mossey CJ, Schmid CH (1995) A model to assess severity and impact of fibromyalgia. J Rheumatol 22:2313–2318PubMed
23.
go back to reference Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145CrossRefPubMed Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145CrossRefPubMed
24.
go back to reference Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE (1992) AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 35:1–10CrossRefPubMed Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE (1992) AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 35:1–10CrossRefPubMed
25.
go back to reference Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172CrossRefPubMed Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172CrossRefPubMed
26.
go back to reference Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19–28CrossRefPubMed Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19–28CrossRefPubMed
27.
go back to reference Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR (2000) Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 27:2683–2691PubMed Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR (2000) Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 27:2683–2691PubMed
28.
go back to reference Freeman EW, Sondheimer SJ, Rickels K (1997) Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 33:303–309PubMed Freeman EW, Sondheimer SJ, Rickels K (1997) Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 33:303–309PubMed
29.
go back to reference Anderberg UM, Liu Z, Berglund L, Nyberg F (1998) Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol 57(Suppl 2):77–80CrossRefPubMed Anderberg UM, Liu Z, Berglund L, Nyberg F (1998) Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol 57(Suppl 2):77–80CrossRefPubMed
30.
go back to reference Hellstrom B, Anderberg UM (2003) Pain perception across the menstrual cycle phases in women with chronic pain. Percept Mot Skills 96:201–211CrossRefPubMed Hellstrom B, Anderberg UM (2003) Pain perception across the menstrual cycle phases in women with chronic pain. Percept Mot Skills 96:201–211CrossRefPubMed
31.
go back to reference Macfarlane TV, Blinkhorn A, Worthington HV, Davies RM, Macfarlane GJ (2002) Sex hormonal factors and chronic widespread pain: a population study among women. Rheumatology (Oxford) 41:454–457CrossRef Macfarlane TV, Blinkhorn A, Worthington HV, Davies RM, Macfarlane GJ (2002) Sex hormonal factors and chronic widespread pain: a population study among women. Rheumatology (Oxford) 41:454–457CrossRef
32.
33.
34.
go back to reference Ostensen M, Rugelsjoen A, Wigers SH (1997) The effect of reproductive events and alterations of sex hormone levels on the symptoms of fibromyalgia. Scand J Rheumatol 26:355–360CrossRefPubMed Ostensen M, Rugelsjoen A, Wigers SH (1997) The effect of reproductive events and alterations of sex hormone levels on the symptoms of fibromyalgia. Scand J Rheumatol 26:355–360CrossRefPubMed
35.
go back to reference Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S (2004) Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161:343–351CrossRefPubMed Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S (2004) Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161:343–351CrossRefPubMed
36.
go back to reference Halbreich U, Kahn LS (2003) Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline. Expert Opin Pharmacother 4:2065–2078CrossRefPubMed Halbreich U, Kahn LS (2003) Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline. Expert Opin Pharmacother 4:2065–2078CrossRefPubMed
37.
go back to reference Bodo C, Rissman EF (2006) New roles for estrogen receptor beta in behavior and neuroendocrinology. Front Neuroendocrinol 27:217–232CrossRefPubMed Bodo C, Rissman EF (2006) New roles for estrogen receptor beta in behavior and neuroendocrinology. Front Neuroendocrinol 27:217–232CrossRefPubMed
38.
39.
go back to reference Meseguer A, Puche C, Cabero A (2002) Sex steroid biosynthesis in white adipose tissue. Horm Metab Res 34:731–736CrossRefPubMed Meseguer A, Puche C, Cabero A (2002) Sex steroid biosynthesis in white adipose tissue. Horm Metab Res 34:731–736CrossRefPubMed
40.
go back to reference Stearns V (2006) Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 5:83–87CrossRefPubMed Stearns V (2006) Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 5:83–87CrossRefPubMed
41.
go back to reference Nagata H, Nozaki M, Nakano H (2005) Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res 31:107–114CrossRefPubMed Nagata H, Nozaki M, Nakano H (2005) Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res 31:107–114CrossRefPubMed
42.
go back to reference Redmond G (1997) Mood disorders in the female patient. Int J Fertil Womens Med 42:67–72PubMed Redmond G (1997) Mood disorders in the female patient. Int J Fertil Womens Med 42:67–72PubMed
43.
go back to reference Wittchen HU, Becker E, Lieb R, Krause P (2002) Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32:119–132CrossRefPubMed Wittchen HU, Becker E, Lieb R, Krause P (2002) Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32:119–132CrossRefPubMed
44.
go back to reference Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S (1991) Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 31:146–152CrossRefPubMed Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S (1991) Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 31:146–152CrossRefPubMed
45.
go back to reference Menkes DB, Coates DC, Fawcett JP (1994) Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 32:37–44CrossRefPubMed Menkes DB, Coates DC, Fawcett JP (1994) Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 32:37–44CrossRefPubMed
46.
go back to reference Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C et al (2006) Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 15:57–69CrossRef Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C et al (2006) Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 15:57–69CrossRef
47.
go back to reference Dobie DJ, Maynard C, Kivlahan DR, Johnson KM, Simpson T, David AC et al (2006) Posttraumatic stress disorder screening status is associated with increased VA medical and surgical utilization in women. J Gen Intern Med 21(Suppl 3):S58–S64CrossRefPubMed Dobie DJ, Maynard C, Kivlahan DR, Johnson KM, Simpson T, David AC et al (2006) Posttraumatic stress disorder screening status is associated with increased VA medical and surgical utilization in women. J Gen Intern Med 21(Suppl 3):S58–S64CrossRefPubMed
48.
go back to reference Ablin JN, Shoenfeld Y, Buskila D (2006) Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. J Autoimmun 27:145–152CrossRefPubMed Ablin JN, Shoenfeld Y, Buskila D (2006) Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. J Autoimmun 27:145–152CrossRefPubMed
49.
go back to reference Amital D, Fostick L, Polliack ML, Segev S, Zohar J, Rubinow A et al (2006) Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities? J Psychosom Res 61:663–669CrossRefPubMed Amital D, Fostick L, Polliack ML, Segev S, Zohar J, Rubinow A et al (2006) Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities? J Psychosom Res 61:663–669CrossRefPubMed
50.
go back to reference Buskila D, Atzeni F, Sarzi-Puttini P (2008) Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev 8:41–43CrossRefPubMed Buskila D, Atzeni F, Sarzi-Puttini P (2008) Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev 8:41–43CrossRefPubMed
51.
go back to reference Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D (2002) Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome? Semin Arthritis Rheum 32:38–50CrossRefPubMed Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D (2002) Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome? Semin Arthritis Rheum 32:38–50CrossRefPubMed
Metadata
Title
The Premenstrual Syndrome and Fibromyalgia—Similarities and Common Features
Authors
Daniela Amital
Calanit Herskovitz
Leah Fostick
Alysa Silberman
Yariv Doron
Joseph Zohar
Alek Itsekson
Matityahu Zolti
Alan Rubinow
Howard Amital
Publication date
01-04-2010
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2-3/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8143-0

Other articles of this Issue 2-3/2010

Clinical Reviews in Allergy & Immunology 2-3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.